Inovio Pharmaceuticals Files 8-K: Material Agreement
Ticker: INO · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $7.693, $7.692, $33.2 m, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: INO
TL;DR
INOVIO just signed a big deal, filing an 8-K. Details TBD.
AI Summary
On April 15, 2024, Inovio Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on other events and filed financial statements and exhibits. Specific details of the agreement and financial information were not provided in this initial filing.
Why It Matters
This filing indicates a significant new agreement for Inovio Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities, and the lack of immediate detail warrants a medium risk assessment.
Key Players & Entities
- Inovio Pharmaceuticals, Inc. (company) — Registrant
- April 15, 2024 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-14888 (string) — Commission File Number
FAQ
What is the nature of the Material Definitive Agreement entered into by Inovio Pharmaceuticals, Inc. on April 15, 2024?
The filing states that Inovio Pharmaceuticals, Inc. entered into a Material Definitive Agreement on April 15, 2024, but the specific terms and details of this agreement are not disclosed in the provided text.
What other items are reported in this 8-K filing besides the Material Definitive Agreement?
In addition to the Material Definitive Agreement, the filing also reports on 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 15, 2024.
What is the Commission File Number for Inovio Pharmaceuticals, Inc.?
The Commission File Number for Inovio Pharmaceuticals, Inc. is 001-14888.
What is the state of incorporation for Inovio Pharmaceuticals, Inc.?
Inovio Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 1,321 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2024-04-17 16:04:01
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
- $7.693 — e (the " Common Stock "), at a price of $7.693 per share and pre-funded warrants to pu
- $7.692 — " Pre-Funded Warrants ") at a price of $7.692 per Pre-Funded Warrant, which represent
- $33.2 m — fering are expected to be approximately $33.2 million, after deducting the underwriting
- $0 — an initial exercise price per share of $0.001, subject to certain adjustments. Th
Filing Documents
- d817715d8k.htm (8-K) — 34KB
- d817715dex11.htm (EX-1.1) — 184KB
- d817715dex41.htm (EX-4.1) — 84KB
- d817715dex51.htm (EX-5.1) — 13KB
- d817715dex991.htm (EX-99.1) — 7KB
- g817715g0417000127865.jpg (GRAPHIC) — 2KB
- 0001193125-24-099067.txt ( ) — 530KB
- ino-20240415.xsd (EX-101.SCH) — 3KB
- ino-20240415_lab.xml (EX-101.LAB) — 18KB
- ino-20240415_pre.xml (EX-101.PRE) — 11KB
- d817715d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. These forward-looking statements include statements about the Offering, such as the expected net proceeds and anticipated closing date. These forward-looking statements, which speak only as of the date of this Current Report, are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the Offering on the anticipated terms or at all. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 6, 2024, and in the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future even
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated April 15, 2024, by and among Inovio Pharmaceuticals, Inc., Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: April 17, 2024 By: /s/ Peter Kies Peter Kies Chief Financial Officer